Canadian Cancer Trials Group IND197: A Phase II Study of Foretinib in Patients with Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2-negative Recurrent or Metastatic Breast Cancer
- Publication date
- 1 May 2016
- Publisher
- Henry Ford Health System Scholarly Commons